LEP Biomedical's core mission is to make glaucoma drainage surgeries 100% successful and relieve the burden associated with post-surgery follow up care.
LEP Biomedical specializes in local ophthalmic drug delivery. Specifically,"HyaGuard" is our biodegradable solution designed to replace patient-administered anti-inflammatory drops. HyaGuard is also designed to be compatible with traditional trabeculectomy surgeries or drainage tubes.
HyaGuard is rapidly and easily inserted into the sub-conjunctival space at the end of a standard surgery. Here, it delivers anti-inflammatory drugs in a controlled manner. This is intended to eliminate the need for self-administered anti-inflammatory drops, decrease post-surgical complications and improve patient quality of life.
Company Details
- Employees
- 3
- Founded
- -
- Address
- Naas, Kildare, Ie
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.lepbiomedical.com/
- HQ
- Naas, Kildare
Lep Biomedical Questions
Lep Biomedical's website is https://www.lepbiomedical.com/
Lep Biomedical's LinkedIn profile is https://ie.linkedin.com/company/lep-biomedical
Lep Biomedical has
3 employees.
View email and phone details for 3
employees at Lep Biomedical.
Lep Biomedical's industry is
Biotechnology Research
Lep Biomedical's top competitors are
Pumpinheart,
Inthelia Therapeutics,
Oncolize,
Cellgebra,
Vertigenius™️,
Plio Surgical,
Tympulse Medical,
Atxa Therapeutics,
Rcsi Innovation,
National Startup Awards.
Lep Biomedical's categories are Biotechnology Research
Lep Biomedical's founding year is 2023
